Post-Hoc Analysis – PharmaLive

New Inclisiran Analysis Evaluated LDL-C Reduction Across Individual Patient

Analysis, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Trials, Data, Elevated Low-Density Lipoprotein Cholesterol (LDL-C), European Medicines Agency (EMA), European Society of Cardiology (ESC) Congress, FDA, Hyperlipidemia, Placebo, Post-Hoc Analysis, Primary Hyperlipidemia, R&D, Small-Interfering RNA (siRNA) Class

Novartis announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual responses of patients on low-density lipoprotein cholesterol (LDL-C) reduction with inclisiran, a first-in-class investigational treatment for hyperlipidemia in adults.

August 30, 2020/by Andrew Humphreys

Novartis’ Crizanlizumab Frees Patients From Sickle Cell Pain Crises, Post Hoc Analysis Shows

Clinical Trials, Post-Hoc Analysis, R&D, Sickle Cell Disease

A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with Novartis’ experimental humanized anti-P-selectin monoclonal antibody crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.

October 10, 2018/by BioSpace